BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 14725821)

  • 1. Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS).
    Winkelman JW; Johnston L
    Sleep Med; 2004 Jan; 5(1):9-14. PubMed ID: 14725821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pramipexole in the management of restless legs syndrome: an extended study.
    Silber MH; Girish M; Izurieta R
    Sleep; 2003 Nov; 26(7):819-21. PubMed ID: 14655914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pramipexole in the treatment of restless legs syndrome: a follow-up study.
    Montplaisir J; Denesle R; Petit D
    Eur J Neurol; 2000 May; 7 Suppl 1():27-31. PubMed ID: 11054156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose pramipexole in the management of restless legs syndrome. An open label trial.
    Stiasny-Kolster K; Oertel WH
    Neuropsychobiology; 2004; 50(1):65-70. PubMed ID: 15179023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Encouraging initial response of restless legs syndrome to pramipexole.
    Becker PM; Ondo W; Sharon D
    Neurology; 1998 Oct; 51(4):1221-3. PubMed ID: 9781569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Augmentation in patients with restless legs syndrome receiving pramipexole therapy: a retrospective study in a single center from China.
    Wang T; Ying M; Zhao R; Zhu D; Zhang L
    Sleep Breath; 2022 Mar; 26(1):373-380. PubMed ID: 33864178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of pregabalin with pramipexole for restless legs syndrome.
    Allen RP; Chen C; Garcia-Borreguero D; Polo O; DuBrava S; Miceli J; Knapp L; Winkelman JW
    N Engl J Med; 2014 Feb; 370(7):621-31. PubMed ID: 24521108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polysomnographic record and successful management of augmentation in restless legs syndrome/Willis-Ekbom disease.
    Maestri M; Fulda S; Ferini-Strambi L; Zucconi M; Marelli S; Staedler C; Bassetti CL; Manconi M
    Sleep Med; 2014 May; 15(5):570-5. PubMed ID: 24767724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A method to switch from oral dopamine agonists to rotigotine in patients with restless legs syndrome and mild augmentation.
    Winkelman JW; Mackie SE; Mei LA; Platt S; Schoerning L
    Sleep Med; 2016 Aug; 24():18-23. PubMed ID: 27810181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and treatment of augmentation in patients with restless legs syndrome: practical recommendations.
    Geyer J; Bogan R
    Postgrad Med; 2017 Sep; 129(7):667-675. PubMed ID: 28818004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term use of pramipexole in the management of restless legs syndrome.
    Lipford MC; Silber MH
    Sleep Med; 2012 Dec; 13(10):1280-5. PubMed ID: 23036265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors affecting the efficacy of pramipexole in patients with restless legs syndrome.
    Rezvani M; Zamani B; Fereshtehnejad SM
    Acta Med Iran; 2013 Jul; 51(6):377-85. PubMed ID: 23852842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Newer dopamine agonists in the treatment of restless legs syndrome.
    Weimerskirch PR; Ernst ME
    Ann Pharmacother; 2001 May; 35(5):627-30. PubMed ID: 11346069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First night efficacy of pramipexole in restless legs syndrome and periodic leg movements.
    Manconi M; Ferri R; Zucconi M; Oldani A; Fantini ML; Castronovo V; Ferini-Strambi L
    Sleep Med; 2007 Aug; 8(5):491-7. PubMed ID: 17512780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The acute effect of a low dosage of pramipexole on severe idiopathic restless legs syndrome: an open-label trial.
    Merlino G; Dolso P; Canesin R; Cancelli I; Valente M; Gigli GL
    Neuropsychobiology; 2006; 54(3):195-200. PubMed ID: 17314491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Restless legs syndrome: differential diagnosis and management with pramipexole.
    Brindani F; Vitetta F; Gemignani F
    Clin Interv Aging; 2009; 4():305-13. PubMed ID: 19750232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Restless legs syndrome augmentation among Japanese patients receiving pramipexole therapy: Rate and risk factors in a retrospective study.
    Takahashi M; Nishida S; Nakamura M; Kobayashi M; Matsui K; Ito E; Usui A; Inoue Y
    PLoS One; 2017; 12(3):e0173535. PubMed ID: 28264052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term treatment of restless legs syndrome with dopamine agonists.
    Ondo W; Romanyshyn J; Vuong KD; Lai D
    Arch Neurol; 2004 Sep; 61(9):1393-7. PubMed ID: 15364685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term open-label study of pramipexole in patients with primary restless legs syndrome.
    Inoue Y; Kuroda K; Hirata K; Uchimura N; Kagimura T; Shimizu T
    J Neurol Sci; 2010 Jul; 294(1-2):62-6. PubMed ID: 20451927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High national rates of high-dose dopamine agonist prescribing for restless legs syndrome.
    Winkelman JW
    Sleep; 2022 Feb; 45(2):. PubMed ID: 34417810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.